ClinicalTrials.gg
Active, not recruitingNCT05629585Updated Oct 14, 2026

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

A Phase 3 interventional study of Dato-DXd and Durvalumab in Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 276 sites in 17 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Updated Oct 14, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,174
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing datopotamab deruxtecan in Breast Neoplasms — 8 open to participants now, 14 under way, 6 of them phase 3. datopotamab deruxtecan · Breast Neoplasms.

Enrollment
3rd of 14
1,174 · median 300
Started
2022
with 1 other
Phase 3
6 of 14
2 open now
Primary completion
2027-09
later than 6 of 13 live
Registered
5th of 14
by date
Lead sponsor
7 of 14
AstraZeneca

Among the 14 studies testing datopotamab deruxtecan in Breast Neoplasms, this one is the 3rd largest by enrollment, is one of 2 that started in 2022, is one of 6 in phase 3, reaches primary completion later than 6 of the 13 other live ones, and was the 5th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 14 studies testing datopotamab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About datopotamab deruxtecan

datopotamab deruxtecan: first FDA approval 2025 (DATROWAY), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing datopotamab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a Phase III, randomized, open-label, 3-arm, multicenter, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with ICT in participants with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy.

Read the detailed description

The study will investigate the efficacy and safety of Dato-DXd with or without durvalumab when compared with ICT (capecitabine and/or pembrolizumab) in participants with stage I to III TNBC who have residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy.

The primary objective of the study is to demonstrate superiority of Dato-DXd in combination with durvalumab relative to ICT by assessment of iDFS in participants with stage I to III TNBC with residual invasive disease at surgical resection following neoadjuvant therapy.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
  • TNBC
  • Triple-negative
  • Adjuvant
  • Datopotamab Deruxtecan
  • Dato-DXd
  • DS1062a
  • Antibody Drug Conjugate
  • ADC
  • TROP2
  • Durvalumab
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be ≥ 18 years at the time of screening.
  2. confirmed invasive TNBC, as defined by the ASCO/CAP guidelines.
  3. Residual invasive disease in the breast and/or axillary lymph node(s) at surgical resection following therapy.
  4. Completed at least 6 cycles of neoadjuvant therapy containing an anthracycline and/or a taxane with or without platinum chemotherapy, with or without pembrolizumab.
  5. No evidence of locoregional or distant relapse.
  6. Surgical removal of all clinically evident disease in the breast and lymph nodes.
  7. performance status of 0 or 1 with no deterioration over the previous 2 weeks prior to randomisation.
  8. All participants must provide an FFPE tumour sample from residual invasive disease at surgery for tissue-based analysis.
  9. No adjuvant systemic therapy.
  10. Radiotherapy (if indicated) delivered before the start of study intervention.
  11. If post-operative radiation therapy is given, an interval of no more than 6 weeks between the completion of radiation therapy and the date of randomisation (radiation therapy can be completed during screening period). If no post-operative radiation therapy is given, an interval of no more than 16 weeks between the date of breast surgery and the date of randomisation.
  12. Has ≥ 50% by either an ECHO or MUGA scan within 28 days before randomisation.
  13. Eligible for one of the therapy options listed as investigator's choice per investigator assessment.
  14. No known germline BRCA1 or BRCA2 pathogenic mutation.
  15. Adequate bone marrow reserve and organ function within 7 days before randomisation.

Exclusion criteria

Exclusion Criteria:

  1. Stage IV () TNBC.
  2. History of prior invasive breast cancer, or evidence of recurrent disease following preoperative therapy and surgery.
  3. Severe or uncontrolled medical conditions including systemic diseases, history of allogeneic organ transplant and active bleeding diseases, ongoing or active infection, serious chronic gastrointestinal conditions associated with diarrhea chronic diverticulitis or previous complicated diverticulitis.
  4. History of another primary except for adequately resected basal cell carcinoma of the skin or squamous cell carcinoma of the skin, in situ disease (including ductal carcinoma in situ) that has undergone potentially curative therapy, or other solid malignancy treated with curative intent with no known active disease within 5 years before randomisation and of low potential risk for recurrence.
  5. Persistent toxicities caused by previous anticancer therapy, excluding alopecia, not yet improved to Grade ≤ 1 or baseline. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention may be included (eg, hearing loss).
  6. Active or prior documented or inflammatory disorders.
  7. corneal disease.
  8. Active or uncontrolled or C virus infection.
  9. Known infection that is not well controlled
  10. Active tuberculosis infection.
  11. Mean resting corrected > 470 ms regardless of gender, obtained from triplicate 12-lead ECGs performed at screening.
  12. Uncontrolled or significant cardiac disease.
  13. History of non-infectious ILD/pneumonitis including radiation, pneumonitis that required , has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
  14. Has severe pulmonary function compromise.
  15. Any known active liver disease.
  16. Grade ≥ 2 peripheral neuropathy of any aetiology.
  17. Prior exposure to a /PD-L1 inhibitor other than pembrolizumab.
  18. Current or prior use of medication within 14 days prior to randomisation.
  19. Participants with a known severe to Dato-DXd or any of the of these products including but not limited to polysorbate 80 or other monoclonal antibodies.
  20. Participants with a known severe hypersensitivity to PD-1/PD-L1 inhibitors.
  21. Participation in another clinical study with a study intervention or medicinal device administered in the last 4 weeks prior to randomisation, randomisation into a prior Dato-DXd, T-DXd, or durvalumab study regardless of treatment assignment.
  22. Currently pregnant (confirmed with positive pregnancy test), breastfeeding or planning to become pregnant.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,174 participants (actual)

Study arms

  • Experimental
    Dato-DXd in combination with Durvalumab

    Arm 1: Dato-DXd 6 mg/kg IV Q3W x 8 cycles + Durvalumab 1120 mg IV Q3W x 9 cycles

    Drug: Dato-DXd · Drug: Durvalumab

  • Experimental
    Dato-DXd

    Arm 2: Dato-DXd 6 mg/kg IV Q3W x 8 cycles

    Drug: Dato-DXd

  • Active comparator
    Investigators Choice Therapy

    Arm 3: Capecitabine (1000 or 1250 mg/m2 oral BID on Days 1 to 14, Q3W) for 8 cycles Pembrolizumab\* (200 mg IV on Day 1, Q3W) for 9 cycles Capecitabine (1000 or 1250 mg/m2 oral BID on Days 1 to 14, Q3W) for 8 cycles + pembrolizumab\* (200 mg IV on Day 1, Q3W) for 9 cycles \* Only participants who have received prior pembrolizumab in the neoadjuvant setting should receive pembrolizumab as part of their adjuvant therapy on Arm 3.

    Drug: Capecitabine · Drug: Pembrolizumab

Interventions

  • Experimental drug. Provided in 100mg vials. IV infusion

    Also known as: Datopotamab deruxtecan (Dato-DXd, DS-1062a)

  • Experimental drug. Provided in 50mg vials. IV infusion

    Also known as: MEDI4736

  • Active Comparator. Tablet. Oral route of administration

    Also known as: XELODA®, Capecitabine Cell Pharm, Capecitabine EG, Capecitabine Accord

  • Active Comparator. Provided in 100mg vials. IV infusion

    Also known as: KEYTRUDA®

06

What researchers measure

Primary outcomes

  1. Invasive disease-free survival (iDFS) for Dato-DXd + durvalumab vs. ICT

    iDFS is defined as time from randomisation until date of first occurrence of one of the following events: ipsilateral invasive breast tumour (local) recurrence, regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and skin of ipsilateral breast), or distant recurrence (metastatic breast cancer that has either been biopsy-confirmed or clinically diagnosed as recurrent invasive breast cancer); contralateral invasive breast cancer; second primary non-breast invasive cancer (other than squamous or basal cell skin cancer); or death from any cause. iDFS will be determined based on disease recurrence per investigator assessment based on all available clinical assessments. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anticancer therapy. The measure of interest will be the HR (hazard ratio) of iDFS for Dato-DXd + durvalumab vs ICT.

    Time frame: From randomisation to date of the event, up to 57 months from first subject in

Secondary outcomes

  1. Distant disease-free survival (DDFS) for Dato-DXd + durvalumab vs ICT

    DDFS is defined as time from randomisation to date of first distant recurrence, occurrence of second primary non-breast invasive cancer, or death from any cause. DDFS is determined based on disease recurrence per investigators assessment based on all available clinical assessments. The analysis will include all randomised participants, as randomised regardless of whether the participant withdraws from randomised therapy or received another anticancer therapy. The measure of interest will be the HR (hazard ratio) of DDFS for Dato-DXd + durvalumab vs ICT.

    Time frame: From randomisation to date of the event, up to 57 months from first subject in

  2. DDFS for Dato-DXd vs ICT

    DDFS is defined as time from randomisation to date of first distant recurrence, occurrence of second primary non-breast invasive cancer, or death from any cause. DDFS is determined based on disease recurrence per investigators assessment based on all available clinical assessments. The measure of interest will be the HR (hazard ratio) of DDFS for Dato-DXd vs ICT.

    Time frame: From randomisation to date of the event, up to 57 months from first subject in

  3. DDFS for Dato-DXd + durvalumab vs Dato-DXd

    DDFS is defined as time from randomisation to date of first distant recurrence, occurrence of second primary non-breast invasive cancer, or death from any cause. DDFS is determined based on disease recurrence per investigators assessment based on all available clinical assessments. The measure of interest will be the HR (hazard ratio) of DDFS for Dato-DXd + durvalumab vs Dato-DXd.

    Time frame: From randomisation to date of the event, up 57 months from first subject in

  4. Overall Survival (OS) for Dato-DXd + durvalumab vs ICT

    OS is defined as time from randomisation until date of death due to any cause. The analysis will include all randomised participants, as randomised regardless of whether the participant withdraws from randomised therapy or received another anticancer therapy. The measure of interest will be the HR (hazard ratio) of OS for Dato-DXd + durvalumab vs ICT.

    Time frame: From randomisation to date of death, due to any cause, up to 87 months from first subject in

  5. OS for Dato-DXd vs ICT

    OS is defined as time from randomisation until date of death due to any cause. The measure of interest will be the HR (hazard ratio) of OS for Dato-DXd vs ICT.

    Time frame: From randomisation to date of death, due to any cause, up to 87 months from first subject in

  6. iDFS for Dato-DXd vs ICT

    iDFS is defined as time from randomisation until date of first occurrence of one of the following events: ipsilateral invasive breast tumour (local) recurrence, regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and skin of ipsilateral breast), or distant recurrence (metastatic breast cancer that has either been biopsy-confirmed or clinically diagnosed as recurrent invasive breast cancer); contralateral invasive breast cancer; second primary non-breast invasive cancer (other than squamous or basal cell skin cancer); or death from any cause. iDFS will be determined based on disease recurrence per investigator assessment based on all available clinical assessments. The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anticancer therapy. The measure of interest will be the HR (hazard ratio) of iDFS for Dato-DXd vs ICT.

    Time frame: From randomisation to date of the event, up to 57 months from first subject in

  7. iDFS for Dato-DXd + durvalumab vs Dato-DXd

    iDFS is defined as time from randomisation until date of first occurrence of one of the following events: ipsilateral invasive breast tumour (local) recurrence, regional invasive breast cancer recurrence (axilla, regional lymph nodes, chest wall, and skin of ipsilateral breast), or distant recurrence (metastatic breast cancer that has either been biopsy-confirmed or clinically diagnosed as recurrent invasive breast cancer); contralateral invasive breast cancer; second primary non-breast invasive cancer (other than squamous or basal cell skin cancer); or death from any cause. The measure of interest will be the HR (hazard ratio) of iDFS for Dato-DXd + durvalumab vs Dato-DXd.

    Time frame: From randomisation to date of the event, up to 57 months from first subject in

  8. Participant-reported physical function in participants treated with Dato-DXd with or without durvalumab compared with ICT

    Time to Deterioration (TTD) and actual scores in physical function as measured by the PROMIS Physical Function Short Form 8c.TTD is defined as time from the date of randomisation to the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analysis will include all dosed participants. The measure of interest is the HR (hazard ratio) of TTD and mean between-arm difference in physical function for Dato-DXd with or without durvalumab compared with ICT.

    Time frame: From randomisation to date of the deterioration, up to 36 months after randomisation

  9. Participant-reported in GHS/QoL in participants treated with Dato-DXd with or without durvalumab compared with ICT

    Time to Deterioration (TTD) and actual scores in GHS/QoL as measured by the GHS/QoL scale from the EORTC IL172. TTD is defined as time from the date of randomisation to the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analysis will include all randomised participants. The measure of interest is the HR (hazard ratio) of TTD and mean between-arm difference in GHS/QoL for Dato-DXd with or without durvalumab compared with ICT.

    Time frame: From randomisation to date of the deterioration, up to 36 months after randomisation

  10. Participant-reported fatigue in participants treated with Dato-DXd with or without durvalumab compared with ICT

    Proportion of participants experiencing different levels of fatigue at 3 months (13weeks), 6 months (26 weeks), and 12 months (52 weeks) as measured by PROMIS Fatigue Short Form 7a. The analysis will include all dosed participants. The measure of interest will be the proportion of participants reporting different levels of fatigue.

    Time frame: From randomisation to 24 months after randomisation

  11. Pharmacokinetics of Dato-DXd

    Concentration of Dato- DXd, total anti-TROP2 antibody, and MAAA-1181 in plasma.

    Time frame: Day 1 of cycles 1,2,4,6,8 (Each cycle is 21 days)

  12. Immunogenicity of Dato-DXd

    Presence of ADAs for Dato-DXd (confirmatory results: positive or negative; titres).

    Time frame: Day 1 of cycles 1,2,4,6,8 (Each cycle is 21 days) and within 35 days of completion of or discontinuation of study intervention (at an average of 6 months following randomization)

  13. Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)

    Safety and tolerability will be evaluated in terms of AEs (graded by CTCAE version 5.0).

    Time frame: Randomization to final safety follow-up visit, either 90 days after last dose of study intervention for those who complete planned study intervention or 90 days after date of discontinuation for those who discontinue study intervention prematurely

07

Study locations

276 sites
  • Research Site
    Gilbert, Arizona 85234, United States
  • Research Site
    Tucson, Arizona 85711, United States
  • Research Site
    Tucson, Arizona 85719, United States
  • Research Site
    Hot Springs, Arkansas 71913, United States
  • Research Site
    Little Rock, Arkansas 72205, United States
  • Research Site
    Springdale, Arkansas 72762, United States
  • Research Site
    Beverly Hills, California 90211, United States
  • Research Site
    Costa Mesa, California 92627, United States
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    Fountain Valley, California 92708, United States
  • Research Site
    Irvine, California 92618, United States
  • Research Site
    La Jolla, California 92093, United States
  • Research Site
    Lakewood, California 90805, United States
  • Research Site
    Los Angeles, California 90017, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Newport Beach, California 92660, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Roseville, California 95661, United States
  • Research Site
    Upland, California 91786, United States
  • Research Site
    Vallejo, California 94589, United States
  • Research Site
    Denver, Colorado 80220, United States
  • Research Site
    New Haven, Connecticut 06510, United States
  • Research Site
    Newark, Delaware 19713, United States
  • Research Site
    Washington D.C., District of Columbia 20007, United States
  • Research Site
    Altamonte Springs, Florida 32701, United States
  • Research Site
    Hollywood, Florida 33021, United States
  • Research Site
    Miami Beach, Florida 33140, United States
  • Research Site
    Tallahassee, Florida 32308, United States
  • Research Site
    West Palm Beach, Florida 33401, United States
  • Research Site
    Athens, Georgia 30607, United States
  • Research Site
    Atlanta, Georgia 30318, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Maywood, Illinois 60153, United States
  • Research Site
    Westwood, Kansas 66205, United States
  • Research Site
    Lexington, Kentucky 40503, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    Louisville, Kentucky 40207, United States
  • Research Site
    Louisville, Kentucky 40241, United States
  • Research Site
    New Orleans, Louisiana 70121, United States
  • Research Site
    Annapolis, Maryland 21401, United States
  • Research Site
    Baltimore, Maryland 21202, United States
  • Research Site
    Columbia, Maryland 21044, United States
  • Research Site
    Boston, Massachusetts 02114, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    St Louis, Missouri 63110, United States
  • Research Site
    Camden, New Jersey 08103, United States
  • Research Site
    Albuquerque, New Mexico 87109, United States
  • Research Site
    New York, New York 10011, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Canton, Ohio 44710, United States
  • Research Site
    Cleveland, Ohio 44106, United States
  • Research Site
    Cleveland, Ohio 44111, United States
  • Research Site
    Cleveland, Ohio 44195, United States
  • Research Site
    Columbus, Ohio 43219, United States
  • Research Site
    Portland, Oregon 97227, United States
  • Research Site
    Hershey, Pennsylvania 17033, United States
  • Research Site
    Philadelphia, Pennsylvania 19111, United States
  • Research Site
    Pittsburgh, Pennsylvania 15213, United States
  • Research Site
    Providence, Rhode Island 02903, United States
  • Research Site
    Germantown, Tennessee 38138, United States
  • Research Site
    Memphis, Tennessee 38120, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Research Site
    Bedford, Texas 76022, United States
  • Research Site
    Dallas, Texas 75246, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Houston, Texas 77024, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Irving, Texas 75063, United States
  • Research Site
    McAllen, Texas 78503, United States
  • Research Site
    Tyler, Texas 75702, United States
  • Research Site
    Fairfax, Virginia 22031, United States
  • Research Site
    Midlothian, Virginia 23114, United States
  • Research Site
    Norfolk, Virginia 23502, United States
  • Research Site
    Reston, Virginia 20190, United States
  • Research Site
    Edmonds, Washington 98026, United States
  • Research Site
    Issaquah, Washington 98029, United States
  • Research Site
    Puyallup, Washington 98373, United States
  • Research Site
    Seattle, Washington 98104, United States
  • Research Site
    Seattle, Washington 98133, United States
  • Research Site
    Spokane Valley, Washington 99216, United States
  • Research Site
    Morgantown, West Virginia 26506, United States
  • Research Site
    Anderlecht, 1070, Belgium
  • Research Site
    Brussels, 1090, Belgium
  • Research Site
    Brussels, 1200, Belgium
  • Research Site
    Charleroi, 6060, Belgium
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Hasselt, 3500, Belgium
  • Research Site
    Liège, 4000, Belgium
  • Research Site
    Namur, 5000, Belgium
  • Research Site
    Sint-Niklaas, 9100, Belgium
  • Research Site
    Wilrijk, 2610, Belgium
  • Research Site
    Brasília, 71681-603, Brazil

Showing the first 100 of 276 sites across 17 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Bardia A, Pusztai L, Albain K, Ciruelos EM, Im SA, Hershman D, Kalinsky K, Isaacs C, Loirat D, Testa L, Tokunaga E, Wu J, Dry H, Barlow W, Kozarski R, Maxwell M, Harbeck N, Sharma P. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan +/- durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther Adv Med Oncol. 2024 Apr 29;16:17588359241248336. doi: 10.1177/17588359241248336. eCollection 2024. PubMed 38686016 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Sep 2027, 57 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 57 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

Completion moved once since we started tracking on Sep 25, 2026: Jan 2030 → Feb 2030, on Oct 14, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2022
First posted
Nov 29, 2022
StartActual
Nov 28, 2022
Primary completionEst.
Sep 1, 2027
CompletionEst.
Feb 28, 2030was Jan 2030
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 20, 2027→Sep 1, 2027
Oct 14, 2026
Study completion
Jan 30, 2030→Feb 28, 2030
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Primary completion Sep 20, 2027→Sep 1, 2027
    Study completion Jan 30, 2030→Feb 28, 2030
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05629585
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo, SWOG Clinical Trials Partnerships, LLC
Responsible party
Sponsor
First posted
Nov 29, 2022
Start date
Nov 28, 2022
Primary completion
Sep 1, 2027 (estimated)
Completion
Feb 28, 2030 (estimated)
Last update
Oct 14, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Datopotamab deruxtecan · Durvalumab

Start the discussion